Title:Prognostic Value and Clinicopathological Differences of Bmi1 in Gastric Cancer: A Meta-analysis
Volume: 16
Issue: 4
Author(s): Bin Yuan, Hong Zhao, Xiaofeng Xue, Jin Zhou, Xu Wang, Ye Han, Lifeng Zhang, Xiaobo Guo and Qiaoming Zhi
Affiliation:
Keywords:
Bmi1, gastric cancer, meta-analysis, prognosis.
Abstract: B cell-specific Moloney murine leukemia virus integration site 1 (Bmi1) was
identified as a biomarker of cancer stem cells, and over-expression of Bmi1 might enhance
tumor aggressive clinical behavior in gastric cancer (GC). Our aim of this meta-analysis is to
investigate the prognostic role and clinicopathological differences of Bmi1 in GC patients. A
total of 6 studies up to September 2014 were included in our study. Our results showed that
there were no relationships between Bmi1 expression and the gender (pooled OR=0.87, 95%CI=0.66-1.14, P=0.319, fixed effect), age
(pooled OR=1.22, 95%CI=0.95-1.59, P=0.126, fixed effect) and differentiation (pooled OR=1.15, 95%CI=0.71-1.86, P=0.582, random
effect) in GC patients. But high Bmi1 expression was significantly correlated with the clinical stage (pooled OR=3.04, 95%CI=1.31-7.07,
P=0.010, random effect), tumor size (pooled OR=2.01, 95%CI=1.14-3.55, P=0.016, random effect), T classification (pooled OR=2.79,
95%CI=1.94-4.03, P<0.001, fixed effect), lymph node metastasis (pooled OR=2.24, 95%CI=1.47-3.39, P<0.001, random effect) and
distant metastasis (pooled OR=5.05, 95%CI=1.29-19.70, P=0.020, random effect), and led to a poor overall survival (OS) in GC patients
(RR=3.38, 95%CI=2.43-4.69, P<0.001, fixed effect). These findings suggested that Bmi1 might serve as a novel and effective prognostic
biomarker in GC, and could be a promising emerging molecular target in GC therapy.
